← Back to Screener
Rockwell Medical, Inc. (DE) Common Stock (RMTI)
Price$0.94
Favorite Metrics
Price vs S&P 500 (26W)-25.68%
Price vs S&P 500 (4W)-22.47%
Market Capitalization$37.03M
All Metrics
P/CF (Annual)8.97x
Book Value / Share (Quarterly)$0.94
P/TBV (Annual)1.20x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-1.65%
Cash Flow / Share (Quarterly)$-0.03
Price vs S&P 500 (YTD)5.48%
Gross Margin (TTM)18.19%
Net Profit Margin (TTM)-7.67%
EPS (TTM)$-0.15
10-Day Avg Trading Volume0.17M
EPS Excl Extra (TTM)$-0.15
Revenue Growth (5Y)2.17%
EPS (Annual)$-0.15
ROI (Annual)-11.34%
Gross Margin (Annual)18.62%
Net Profit Margin (5Y Avg)-19.33%
Cash / Share (Quarterly)$0.63
Revenue Growth QoQ (YoY)-25.62%
ROA (Last FY)-9.30%
Revenue Growth TTM (YoY)-31.76%
EBITD / Share (TTM)$-0.07
ROE (5Y Avg)-294.82%
Operating Margin (TTM)-6.77%
Cash Flow / Share (Annual)$-0.03
P/B Ratio1.00x
P/B Ratio (Quarterly)0.89x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)0.52x
Net Interest Coverage (TTM)-7.53x
ROA (TTM)-9.61%
EV / EBITDA (TTM)40.38x
EPS Incl Extra (Annual)$-0.15
Current Ratio (Annual)3.98x
Quick Ratio (Quarterly)3.46x
3-Month Avg Trading Volume0.56M
52-Week Price Return-11.29%
EV / Free Cash Flow (Annual)10.71x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.69
P/S Ratio (Annual)0.53x
Asset Turnover (Annual)1.21x
52-Week High$2.10
Operating Margin (5Y Avg)-17.24%
EPS Excl Extra (Annual)$-0.15
CapEx CAGR (5Y)-12.39%
Tangible BV CAGR (5Y)-3.65%
26-Week Price Return-16.94%
Quick Ratio (Annual)3.46x
13-Week Price Return-4.57%
Total Debt / Equity (Annual)0.27x
Current Ratio (Quarterly)3.98x
Enterprise Value$36.181
Revenue / Share Growth (5Y)-26.63%
Asset Turnover (TTM)1.25x
Book Value / Share Growth (5Y)-25.23%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)12.25x
Pretax Margin (Annual)-7.67%
Cash / Share (Annual)$0.63
3-Month Return Std Dev86.55%
Gross Margin (5Y Avg)9.59%
Net Income / Employee (TTM)$-0
ROE (Last FY)-14.37%
Net Interest Coverage (Annual)-7.53x
EPS Basic Excl Extra (Annual)$-0.15
P/FCF (TTM)9.53x
Receivables Turnover (TTM)8.43x
Total Debt / Equity (Quarterly)0.27x
EPS Incl Extra (TTM)$-0.15
Receivables Turnover (Annual)8.43x
ROI (TTM)-12.05%
P/S Ratio (TTM)0.53x
Pretax Margin (5Y Avg)-19.33%
Revenue / Share (Annual)$1.93
Tangible BV / Share (Annual)$0.69
Price vs S&P 500 (52W)-46.39%
Year-to-Date Return9.62%
5-Day Price Return-2.79%
EPS Normalized (Annual)$-0.15
ROA (5Y Avg)-26.72%
Net Profit Margin (Annual)-7.67%
Month-to-Date Return2.30%
Cash Flow / Share (TTM)$-0.70
EBITD / Share (Annual)$-0.07
Operating Margin (Annual)-6.77%
LT Debt / Equity (Annual)0.24x
ROI (5Y Avg)-51.24%
LT Debt / Equity (Quarterly)0.24x
EPS Basic Excl Extra (TTM)$-0.15
P/TBV (Quarterly)1.20x
P/B Ratio (Annual)0.89x
Inventory Turnover (TTM)12.32x
Pretax Margin (TTM)-7.67%
Book Value / Share (Annual)$0.94
Price vs S&P 500 (13W)-7.44%
Beta1.70x
P/FCF (Annual)11.60x
Revenue / Share (TTM)$1.76
ROE (TTM)-15.64%
52-Week Low$0.78
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.13
4.13
4.13
4.13
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
RMTIRockwell Medical, Inc. (DE) Common Stock | 0.53x | -31.76% | 18.19% | — | $0.94 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Rockwell Medical Inc manufactures and distributes dialysis concentrates—essential consumables used in hemodialysis treatment. The company supplies liquid and dry bicarbonate and acid formulations, including CitraPure, RenalPure, and SteriLyte, to dialysis providers across the United States. It operates in a stable, recurring-revenue market driven by the ongoing treatment needs of dialysis patients.